Literature DB >> 28275476

Serum KL-6 in pulmonary alveolar proteinosis: China compared historically with Germany and Japan.

Wen-Liang Guo1, Zi-Qing Zhou1, Lu Chen1, Zhu-Quan Su1, Chang-Hao Zhong1, Yu Chen1, Shi-Yue Li1.   

Abstract

BACKGROUND: KL-6 is a biomarker of the severity of pulmonary alveolar proteinosis (PAP). We noticed a significant difference in the mean serum KL-6 level between Japanese and Caucasian patients. To assess the clinical value of serum KL-6 in Chinese PAP patients, and to compare the differences in serum KL-6 levels in Chinese patients and patients of other ethnicities.
METHODS: From 2014-2016, we prospectively examined 37 Chinese Han patients with PAP, measured their serum KL-6 levels, evaluated the correlation between initial KL-6 levels and clinical variables, and compared our results with studies from Japan and Germany (similar methods were used). We searched dbSNP for the MUC1 568 (rs4072037) genotype or allele frequency distributions in China, Japan, and Germany.
RESULTS: Initial serum KL-6 levels were significantly correlated with baseline PaO2, A-aDO2, DLCO, FVC, and LDH levels (all P<0.001). Compared with Chinese PAP patients, the mean serum KL-6 level was significantly lower in German PAP patients (P<0.001) but not in Japanese PAP patients (P>0.4). In the rs4072037 allele frequency distributions, the frequency of the A/A genotype was significantly higher while that of the G/G genotype was significantly lower in Chinese and Japanese cohorts than in Caucasian cohorts (both P<0.001).
CONCLUSIONS: Serum KL-6 can be used as a biological indicator for disease monitoring in Chinese patients. The difference in serum KL-6 level among Chinese, German, and Japanese PAP patients may be associated with the distribution of the rs4072037 genotype.

Entities:  

Keywords:  KL-6; MUC1; pulmonary alveolar proteinosis (PAP); whole lung lavage (WLL)

Year:  2017        PMID: 28275476      PMCID: PMC5334078          DOI: 10.21037/jtd.2017.02.14

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  13 in total

Review 1.  Pulmonary alveolar proteinosis.

Authors:  Bruce C Trapnell; Jeffrey A Whitsett; Koh Nakata
Journal:  N Engl J Med       Date:  2003-12-25       Impact factor: 91.245

2.  [The clinical significance of the levels of serum KL-6 mucin and interleukin-13 in pulmonary alveolar proteinosis].

Authors:  Jingzhu Zhou; Yonglong Xiao; Jingjing Ding; Kefeng Zhou; Zhengyang Zhou; Hourong Cai
Journal:  Zhonghua Jie He He Hu Xi Za Zhi       Date:  2015-02

3.  Direct evidence that GM-CSF inhalation improves lung clearance in pulmonary alveolar proteinosis.

Authors:  Kazumasa Ohashi; Atsuyasu Sato; Toshinori Takada; Toru Arai; Takahito Nei; Yasunori Kasahara; Natsuki Motoi; Masayuki Hojo; Shinya Urano; Haruyuki Ishii; Masanori Yokoba; Ryosuke Eda; Hideaki Nakayama; Yasuyuki Nasuhara; Yoshiko Tsuchihashi; Chinatsu Kaneko; Hiroko Kanazawa; Masahito Ebina; Etsuro Yamaguchi; Jacqueline Kirchner; Yoshikazu Inoue; Koh Nakata; Ryushi Tazawa
Journal:  Respir Med       Date:  2011-11-22       Impact factor: 3.415

4.  Pulmonary alveolar proteinosis: prospective clinical experience in 23 patients for 15 years.

Authors:  K Kariman; J A Kylstra; A Spock
Journal:  Lung       Date:  1984       Impact factor: 2.584

5.  The mucin-1 568 adenosine to guanine polymorphism influences serum Krebs von den Lungen-6 levels.

Authors:  Rob Janssen; Adrian Kruit; Jan C Grutters; Henk J Ruven; Wim B Gerritsen; Jules M van den Bosch
Journal:  Am J Respir Cell Mol Biol       Date:  2005-12-15       Impact factor: 6.914

6.  Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis.

Authors:  Ryushi Tazawa; Bruce C Trapnell; Yoshikazu Inoue; Toru Arai; Toshinori Takada; Yasuyuki Nasuhara; Nobuyuki Hizawa; Yasunori Kasahara; Koichiro Tatsumi; Masayuki Hojo; Haruyuki Ishii; Masanori Yokoba; Naohiko Tanaka; Etsuro Yamaguchi; Ryosuke Eda; Yoshiko Tsuchihashi; Konosuke Morimoto; Masanori Akira; Masaki Terada; Junji Otsuka; Masahito Ebina; Chinatsu Kaneko; Toshihiro Nukiwa; Jeffrey P Krischer; Kohei Akazawa; Koh Nakata
Journal:  Am J Respir Crit Care Med       Date:  2010-02-18       Impact factor: 21.405

7.  Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan.

Authors:  Yoshikazu Inoue; Bruce C Trapnell; Ryushi Tazawa; Toru Arai; Toshinori Takada; Nobuyuki Hizawa; Yasunori Kasahara; Koichiro Tatsumi; Masaaki Hojo; Toshio Ichiwata; Naohiko Tanaka; Etsuro Yamaguchi; Ryosuke Eda; Kazunori Oishi; Yoshiko Tsuchihashi; Chinatsu Kaneko; Toshihiro Nukiwa; Mitsunori Sakatani; Jeffrey P Krischer; Koh Nakata
Journal:  Am J Respir Crit Care Med       Date:  2008-01-17       Impact factor: 21.405

8.  Physiologic effects of bronchopulmonary lavage in alveolar proteinosis.

Authors:  R M Rogers; D C Levin; B A Gray; L W Moseley
Journal:  Am Rev Respir Dis       Date:  1978-08

9.  Serum and bronchoalveolar fluid KL-6 levels in patients with pulmonary alveolar proteinosis.

Authors:  T Takahashi; M Munakata; I Suzuki; Y Kawakami
Journal:  Am J Respir Crit Care Med       Date:  1998-10       Impact factor: 21.405

10.  Serum KL-6 is a predictor of outcome in pulmonary alveolar proteinosis.

Authors:  Francesco Bonella; Shinichiro Ohshimo; Cai Miaotian; Matthias Griese; Josune Guzman; Ulrich Costabel
Journal:  Orphanet J Rare Dis       Date:  2013-04-04       Impact factor: 4.123

View more
  3 in total

1.  An exploratory study investigating biomarkers associated with autoimmune pulmonary alveolar proteinosis (aPAP).

Authors:  Ilaria Campo; Federica Meloni; Martina Gahlemann; Wiebke Sauter; Carina Ittrich; Corinna Schoelch; Bruce C Trapnell; Abhya Gupta
Journal:  Sci Rep       Date:  2022-05-24       Impact factor: 4.996

Review 2.  The Occupational Burden of Nonmalignant Respiratory Diseases. An Official American Thoracic Society and European Respiratory Society Statement.

Authors:  Paul D Blanc; Isabella Annesi-Maesano; John R Balmes; Kristin J Cummings; David Fishwick; David Miedinger; Nicola Murgia; Rajen N Naidoo; Carl J Reynolds; Torben Sigsgaard; Kjell Torén; Denis Vinnikov; Carrie A Redlich
Journal:  Am J Respir Crit Care Med       Date:  2019-06-01       Impact factor: 21.405

3.  Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome.

Authors:  Sara Remuzgo-Martínez; Belén Atienza-Mateo; J Gonzalo Ocejo-Vinyals; Fernanda Genre; Verónica Pulito-Cueto; Víctor M Mora-Cuesta; David Iturbe-Fernández; Leticia Lera-Gómez; Raquel Pérez-Fernández; Diana Prieto-Peña; Juan Irure; Fredeswinda Romero-Bueno; Olga Sanchez-Pernaute; Rodrigo Alonso-Moralejo; Laura Nuño; Gema Bonilla; Esther F Vicente-Rabaneda; Ignacio Grafia; Sergio Prieto-González; Javier Narvaez; Ernesto Trallero-Araguas; Albert Selva-O'Callaghan; Oreste Gualillo; Lorenzo Cavagna; José M Cifrián; Elisabetta A Renzoni; Santos Castañeda; Raquel López-Mejías; Miguel A González-Gay
Journal:  Sci Rep       Date:  2021-11-19       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.